Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review, 13120-13121 [2017-04623]
Download as PDF
<![CDATA[
13120
Federal Register / Vol. 82, No. 45 / Thursday, March 9, 2017 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Advisory Council for the Elimination of
Tuberculosis: Notice of Charter
Renewal
This gives notice under the Federal
Advisory Committee Act (Pub. L. 92–
463) of October 6, 1972, that the
Advisory Council for the Elimination of
Tuberculosis, Department of Health and
Human Services, has been renewed for
a 2-year period through March 15, 2019.
For information, contact Hazel Dean,
Sc.D., M.P.H., Designated Federal
Officer, Advisory Council for the
Elimination of Tuberculosis,
Department of Health and Human
Services, 1600 Clifton Road NE.,
Mailstop E–10, Atlanta, Georgia 30333,
telephone 404/639–8000 or fax 404/
639–8600.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2017–04616 Filed 3–8–17; 8:45 am]
BILLING CODE 4163–18–P
asabaliauskas on DSK3SPTVN1PROD with NOTICES
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2017–04624 Filed 3–8–17; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
BILLING CODE 4163–18–P
Advisory Committee to the Director
(ACD), Centers for Disease Control and
Prevention (CDC)—Health Disparities
Subcommittee (HDS)
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following meeting of the
aforementioned committee:
Time and Date: 8:30 p.m.–4:00 p.m.,
EDT, April 19, 2017.
Place: Centers for Disease Control &
Prevention (CDC), Global
Communications Center, Building 19,
Rooms 254/255, 1600 Clifton Road NE.,
Atlanta, Georgia 30329.
Status: Open to the public, limited
only by the space and phone lines
available. The meeting room
Jkt 241001
Place: Teleconference.
Status: The meeting will be closed to
the public in accordance with
provisions set forth in Section 552b(c)
(4) and (6), Title 5 U.S.C., and the
Determination of the Director,
Management Analysis and Services
Office, CDC, pursuant to Public Law 92–
463.
Matters for Discussion: The meeting
will include the initial review,
discussion, and evaluation of
applications received in response to
‘‘Natural Experiments of Policy and
Built Environment Impact on Diabetes
Risk’’, FOA D P17–003.
Contact Person for More Information:
Jaya Raman Ph.D., Scientific Review
Officer, CDC, 4770 Buford Highway,
Mailstop F80, Atlanta, Georgia 30341,
Telephone: (770) 488–6511, kva5@
cdc.gov.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
[FR Doc. 2017–04619 Filed 3–8–17; 8:45 am]
Centers for Disease Control and
Prevention
17:43 Mar 08, 2017
Times and Dates:
10:00 a.m.–6:00 p.m., EDT, April 12,
2017 (Closed)
10:00 a.m.–6:00 p.m., EDT, April 13,
2017 (Closed)
Elain L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention (CDC).
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
VerDate Sep<11>2014
accommodates approximately 60
people. Advance registration for inperson participation is required by April
5, 2017. The public is welcome to
participate during the public comment
period, which is tentatively scheduled
from 3:45 p.m. to 3:55 p.m. This
meeting will also be available by
teleconference. Please dial (866) 918–
8397 and enter code 9346283.
Purpose: The Subcommittee will
provide advice to the CDC Director
through the ACD on strategic and other
health disparities and health equity
issues and provide guidance on
opportunities for CDC.
Matters for Discussion: The Health
Disparities Subcommittee members will
receive an update on selected
recommendations of the HDS, and on
progress toward Health Equity and
Public Health Accreditation.
Agenda items are subject to change as
priorities dictate.
Contact Person for More Information:
Leandris Liburd, Ph.D., M.P.H., M.A.,
Designated Federal Officer, Health
Disparities Subcommittee, Advisory
Committee to the Director, CDC, 1600
Clifton Road NE., M/S K–77, Atlanta,
Georgia 30329. Telephone (404) 498–
6482, Email: ACDirector@cdc.gov.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Initial Review
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces a meeting for the initial
review of applications in response to
Funding Opportunity Announcement
(FOA) DP17–003, Natural Experiments
of Policy and Built Environment Impact
on Diabetes Risk.
PO 00000
Frm 00032
Fmt 4703
Sfmt 4703
BILLING CODE 4163–18–P
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Initial Review
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces a meeting for the initial
review of applications in response to
Funding Opportunity Announcement
(FOA) DP17–002, Validation of Survey
Questions to Distinguish Type 1 and
Type 2 Diabetes among Adults with
Diabetes.
Time and Date: 10:00 a.m.–6:00 p.m.,
EDT, April 5, 2017 (Closed).
Place: Teleconference.
E:\FR\FM\09MRN1.SGM
09MRN1
Federal Register / Vol. 82, No. 45 / Thursday, March 9, 2017 / Notices
Status: The meeting will be closed to
the public in accordance with
provisions set forth in Section 552b(c)
(4) and (6), Title 5 U.S.C., and the
Determination of the Director,
Management Analysis and Services
Office, CDC, pursuant to Public Law 92–
463.
Matters for Discussion: The meeting
will include the initial review,
discussion, and evaluation of
applications received in response to
‘‘Validation of Survey Questions to
Distinguish Type 1 and Type 2 Diabetes
among Adults with Diabetes’’, FOA
DP17–002.
Contact Person for More Information:
Jaya Raman Ph.D., Scientific Review
Officer, CDC, 4770 Buford Highway,
Mailstop F80, Atlanta, Georgia 30341,
Telephone: (770) 488–6511, kva5@
cdc.gov.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2017–04623 Filed 3–8–17; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
asabaliauskas on DSK3SPTVN1PROD with NOTICES
Clinical Laboratory Improvement
Advisory Committee
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following committee
meeting.
Times and Dates:
8:30 a.m.–5:00 p.m., EDT, April 12,
2017
8:30 a.m.–12:00 p.m., EDT, April 13,
2017
Place: CDC, 1600 Clifton Road NE.,
Tom Harkin Global Communications
Center, Building 19, Auditorium B,
Atlanta, Georgia 30333.
Status: Open to the public, limited
only by the space available. The meeting
room accommodates approximately 100
people. This meeting will also be
webcast, please see information below.
VerDate Sep<11>2014
17:43 Mar 08, 2017
Jkt 241001
Purpose: This Committee is charged
with providing scientific and technical
advice and guidance to the Secretary of
Health and Human Services (HHS); the
Assistant Secretary for Health; the
Director, Centers for Disease Control
and Prevention; the Commissioner,
Food and Drug Administration (FDA);
and the Administrator, Centers for
Medicare and Medicaid Services (CMS).
The advice and guidance pertain to
general issues related to improvement in
clinical laboratory quality and
laboratory medicine practice and
specific questions related to possible
revision of the Clinical Laboratory
Improvement Amendment (CLIA)
standards. Examples include providing
guidance on studies designed to
improve safety, effectiveness, efficiency,
timeliness, equity, and patientcenteredness of laboratory services;
revisions to the standards under which
clinical laboratories are regulated; the
impact of proposed revisions to the
standards on medical and laboratory
practice; and the modification of the
standards and provision of nonregulatory guidelines to accommodate
technological advances, such as new
test methods, the electronic
transmission of laboratory information,
and mechanisms to improve the
integration of public health and clinical
laboratory practices.
Matters for Discussion: The agenda
will include agency updates from CDC,
CMS, and FDA. Presentations and
discussions will focus on the
implementation of next generation
sequencing in clinical laboratories;
laboratory testing in the era of
telemedicine; and a report from the
Institute of Medicine (IOM) CLIAC
workgroup.
Agenda items are subject to change as
priorities dictate.
Webcast: The meeting will also be
webcast. Persons interested in viewing
the webcast can access information at:
https://
cdclabtraining.adobeconnect.com/
aprilcliac/.
Online Registration Required: All
people attending the CLIAC meeting inperson are required to register for the
meeting online at least 5 business days
in advance for U.S. citizens and at least
10 business days in advance for
international registrants. Register at:
https://wwwn.cdc.gov/cliac/Meetings/
MeetingDetails.aspx. Register by
scrolling down and clicking the
‘‘Register for this Meeting’’ button and
completing all forms according to the
instructions given. Please complete all
the required fields before submitting
your registration and submit no later
than April 5, 2017 for U.S. registrants
PO 00000
Frm 00033
Fmt 4703
Sfmt 4703
13121
and March 29, 2017 for international
registrants.
Providing Oral or Written Comments:
It is the policy of CLIAC to accept
written public comments and provide a
brief period for oral public comments on
agenda items. Public comment periods
for each agenda item are scheduled
immediately prior to the Committee
discussion period for that item.
Oral Comments: In general, each
individual or group requesting to make
oral comments will be limited to a total
time of five minutes (unless otherwise
indicated). Speakers must also submit
their comments in writing for inclusion
in the meeting’s Summary Report. To
assure adequate time is scheduled for
public comments, speakers should
notify the contact person below at least
one week prior to the meeting date.
Written Comments: For individuals or
groups unable to attend the meeting,
CLIAC accepts written comments until
the date of the meeting (unless
otherwise stated). However, it is
requested that comments be submitted
at least one week prior to the meeting
date so that the comments may be made
available to the Committee for their
consideration and public distribution.
Written comments, one hard copy with
original signature, should be provided
to the contact person at the mailing or
email address below, and will be
included in the meeting’s Summary
Report.
Availability of Meeting Materials: To
support the green initiatives of the
federal government, the CLIAC meeting
materials will be made available to the
Committee and the public in electronic
format (PDF) on the internet instead of
by printed copy. Check the CLIAC Web
site on the day of the meeting for
materials: https://wwwn.cdc.gov/cliac/
Meetings/MeetingDetails.aspx. Note: If
using a mobile device to access the
materials, please verify that the device’s
browser is able to download the files
from the CDC’s Web site before the
meeting.
Alternatively, the files can be
downloaded to a computer and then
emailed to the portable device. An
internet connection, power source, and
limited hard copies may be available at
the meeting location, but cannot be
guaranteed.
Contact Person for Additional
Information: Nancy Anderson, Chief,
Laboratory Practice Standards Branch,
Division of Laboratory Systems, Center
for Surveillance, Epidemiology and
Laboratory Services, Office of Public
Health Scientific Services, CDC, 1600
Clifton Road NE., Mailstop F–11,
Atlanta, Georgia 30329–4018; telephone
E:\FR\FM\09MRN1.SGM
09MRN1
]]>Agencies
[Federal Register Volume 82, Number 45 (Thursday, March 9, 2017)]
[Notices]
[Pages 13120-13121]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-04623]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Disease, Disability, and Injury Prevention and Control Special
Emphasis Panel (SEP): Initial Review
In accordance with Section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC) announces a meeting for the initial review of
applications in response to Funding Opportunity Announcement (FOA)
DP17-002, Validation of Survey Questions to Distinguish Type 1 and Type
2 Diabetes among Adults with Diabetes.
Time and Date: 10:00 a.m.-6:00 p.m., EDT, April 5, 2017 (Closed).
Place: Teleconference.
[[Page 13121]]
Status: The meeting will be closed to the public in accordance with
provisions set forth in Section 552b(c) (4) and (6), Title 5 U.S.C.,
and the Determination of the Director, Management Analysis and Services
Office, CDC, pursuant to Public Law 92-463.
Matters for Discussion: The meeting will include the initial
review, discussion, and evaluation of applications received in response
to ``Validation of Survey Questions to Distinguish Type 1 and Type 2
Diabetes among Adults with Diabetes'', FOA DP17-002.
Contact Person for More Information: Jaya Raman Ph.D., Scientific
Review Officer, CDC, 4770 Buford Highway, Mailstop F80, Atlanta,
Georgia 30341, Telephone: (770) 488-6511, kva5@cdc.gov.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining to
announcements of meetings and other committee management activities,
for both the Centers for Disease Control and Prevention and the Agency
for Toxic Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 2017-04623 Filed 3-8-17; 8:45 am]
BILLING CODE 4163-18-P
